Mobile

A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-000145-35

A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

(1) After 30 weeks, to assess the effect of the addition of sitagliptin compared with glimepiride on HbA1c. (2) To assess the safety and the tolerability of sitagliptin compared with glimepiride.

Critère d'inclusion

  • type II diabetes mellitus

Liens